Microbix Biosystems Inc. · TSX:MBX

Microbix Biosystems — Investor Presentation (May 2023)

23 slides from Microbix Biosystems's investor presentation, May 12, 2023

  1. Slide 1: Supporting the Global Diagnostics Industry

    Supporting the Global Diagnostics Industry Corporate Presentation – Spring, 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements • This presentation contains forward-looking statements about trends and objectives. • Risks and uncertainties related to such statements could cause actual outcomes to differ materially. • Such risks include, among others, those related to operations, customers or markets

  3. Slide 3: Microbix Senior Management

    Microbix Senior Management Cameron L. Groome Jim Currie, CPA Ken Hughes, Ph.D. CEO, President, and Director Chief Financial Officer Chief Operating Officer • Has served on the MBX BoD and AC since • Joined MBX as CFO in 2016 after • Executive and biomedical scientist with 25 2012, and was appointed

  4. Slide 4: Microbix Board of Directors

    Microbix Board of Directors Martin Marino Dr. Peter M. Blecher Mark A. Cochran, Ph.D. Board Chairman Director HRGC Chair • Mr. Marino has more than 30 years’ • Dr. Blecher worked as an Emergency Room • Dr. Cochran was Executive Director of Johns experience in corporate legal roles and physician for

  5. Slide 5: Financials – Microbix Capital Structure

    Financials – Microbix Capital Structure 0.9 3000000 0.8 2500000 0.7 0.6 2000000 0.5 1500000 0.4 0.3 1000000 0.2 500000 0.1 0 0 TSX LISTED, SYMBOL: MBX • OTC QX LISTED, SYMBOL: MBXBF Analyst Coverage Current Price $0.38 (May 9) Market Capitalization $51.2M Shares Outstanding 138.3M** Avg. Daily Volum

  6. Slide 6: Products & Customers Across the Diagnostic Testing Industry

    Products & Customers Across the Diagnostic Testing Industry Supporting over 100 diagnostics, clinical lab, and lab-proficiency related customers worldwide Pre-Analytical Test Collection Devices (DxTM™) Peri-Analytical Test Ingredients (Antigens) Pan-Analytical QMS support Leveraging Microbix’s Test

  7. Slide 7: Microbix – Historical Revenue

    Microbix – Historical Revenue Pandemic Microbix expanded its two new higher-margin product segments of DxTM and QAPs over the past two years, achieving record sales. Its overall sales growth is targeted to continue. 2022 7

  8. Slide 8: Microbix's Business Objectives – The Next Five Years

    Microbix’s Business Objectives – The Next Five Years Attain Revenues of C$ 100 million per year by way of: 1. Cross-Selling – Sell every product 2. New Clients – Identify & secure new category across existing customer- Dx industry clients with over C$ 1 million base of >100 Dx industry firms . per y

  9. Slide 9: In-Vitro Diagnostics Market – Growth Opportunities for Microbix

    In-Vitro Diagnostics Market – Growth Opportunities for Microbix TEST COLLECTION TEST INGREDIENTS TEST CONTROLS DEVICES & REAGENTS DxTM & Others Antigens QAPs™ • Pre-COVID, Canada imported an • Antigens to make immunoassays • QAPs mainly support accuracy estimated C$ 50 million per year – tests detec

  10. Slide 10: Test Collection Devices – DxTM (VTM) & Others

    Test Collection Devices – DxTMTM (VTM) & Others Sample Collection Devices (SCDs) Most lab-based PCR tests conducted require a vial of VTM, all of which was Sales Potential for SCDs imported. SCD needs continue, driven by both respiratory viruses and the ongoing need to test for many other infectious

  11. Slide 11: Test Ingredients - Antigens

    Test Ingredients - Antigens Grow, purify, and inactivate native bacteria and viruses for use as antigens for more than 100 leading international diagnostic companies . Microbix provides antigens on a large scale for major international diagnostic manufacturers, most often as a critical sole-source s

  12. Slide 12: Test Ingredients - Antigens

    Test Ingredients - Antigens Growth Outlook for this Business Area In f2022, Antigens comprised As healthcare re-stabilizes, Antigen sales should benefit from <50% of sales, down from 90% greater global attention to respiratory and infectious disease historically due to growth of testing as a result

  13. Slide 13: QAPs – Ensuring Test and Test-Workflow Accuracy

    QAPs™ – Ensuring Test and Test-Workflow Accuracy Example: QAPs™ Human Papillomavirus (HPV) MDx Panel For use in laboratory-based testing MBX is the sole provider of quality control materials for extended HPV genotyping panels • HPV molecular diagnostics market is ~US$ 800M at YE 2022, with 5-10% acc

  14. Slide 14: QAPs – Ensuring Test and Test-Workflow Accuracy

    QAPs™ – Ensuring Test and Test-Workflow Accuracy Example: QAPs™ Supporting Point-of-Care Tests (PoCTs) across multiple pathogens & settings MBX uniquely able to provide FLOQswab® format control materials for PoCT support • Replicates the sample-collection workflow and provides consistent sample upta

  15. Slide 15: Test Controls - Quality Assessment Products (QAPs)

    Test Controls - Quality Assessment Products (QAPs™) QAPs™ Competitive Advantages 1. Performance – QAPs are whole- 2. Formats – Having vials & FLOQSwab® genome and whole-workflow to formats enable support of both lab- prevent systemic errors based & point-of-care testing 3. Stability – Proven stabili

  16. Slide 16: Test Controls - Quality Assessment Products (QAPs)

    Test Controls - Quality Assessment Products (QAPs™) Product Lines & Key Achievements Product Line Sales Potential Target Market(s) Current & Targeted • Licensed/ registered for sale in Canada, EU, U.S, and Australia Currently ~C$ 1M/yr • Sold directly to clinical lab chains or via distributors (via

  17. Slide 17: Kinlytic Urokinase

    Kinlytic® Urokinase Partnering Opportunity for re-launch of a LMW cell-culture derived urokinase → Kinlytic® Urokinase Specific Kinlytic Activities: Microbix’s expertise in biologicals Refined Project Scope Established Precise Costs led to its securing rights to this Catheter Clearance Indication Qu

  18. Slide 18: Operations - Now Developing & Launching Many New Products Each Year

    Operations - Now Developing & Launching Many New Products Each Year Microbix’s product lines are rapidly expanding, as is our base of customers. April 2022 – HPV Panel Results Presented at EUROGIN April 2022 – Respiratory Multiplex at ECCMID, LabQuality Days, & ASM’s CVS June 2022 – SARS-CoV2 Swab R

  19. Slide 19: Operations - 2022 Highlights

    Operations - 2022 Highlights • Microbix now has approximately 110 staff • CE Mark and FDA Registrations for 22 IVD “REDx” Molecular Test Controls • HPV-31, 33, 39, 51, 52, 66 • Multiplex Respiratory, • SARS-CoV-2 variants • Multiplex HSV1&2/VZV/Syphilis • UK Variant M. genitalium, • Negative Control

  20. Slide 20: Financials – A Review of Fiscal 2022

    Financials – A Review of Fiscal 2022 Fiscal 2022 Results: A Flattish Year as Company Invests in Growth • Record revenue of $19.1M in f2022 • In f2022, created & launched 22 new products with its QAPs and sales from this segment grew 14% y/y. • Antigen sales slightly slower until Q4 f2022, when they

  21. Slide 21: Financials – The Past Several Years

    Financials – The Past Several Years Financial Results – 2017 to 2023 YTD Revenue Gross Margin Financial EBITDA $000's D/E & Current Ratio Performance 9 8 7 6 5 4 3 2 1 0 2017 2018 2019 2020 2021 2022 YTD 2023 D/E Current Ratio 21

  22. Slide 22: Key Takeaways about Microbix

    Key Takeaways about Microbix Highlights & Catalysts Proven ability to grow revenues Successfully managing multiple lines of (to new records for F’22 & ‘21) business & many customer relationships TSX-listed, on OTC QX, positive Earnings Strong cash balance and working & Cash Flow (F’22 & ‘21), equity

  23. Slide 23: Thank You

    THANK YOU Corporate Presentation – Spring, 2023 Cameron Groome CEO, President, and Director cameron.groome@microbix.com 23

Microbix Biosystems — Investor Presentation (May 2023) on 6ix